Clinical Trial Update: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enobosarm as monotherapy for AR+/ER+/HER2- metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enobosarm (enobosarm)

Snippet

Sponsor: Veru Inc. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: TERMINATED